Advertisement

Pancreatic Cancer

  • Jennifer S. Chang
  • Mekhail Anwar
Chapter

Abstract

This chapter will discuss the epidemiology, workup, management, treatment, and follow-up for pancreatic cancer.

Keywords

Pancreatic cancer 

Notes

Acknowledgment

We thank Jennifer S. Yu MD, PhD, Joy Coleman MD, and Jeanne Marie Quivey MD, FACR, for their work on the prior edition of this chapter.

References

  1. Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(22):2654–68.CrossRefPubMedGoogle Scholar
  2. Berger AC, Garcia M Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26(36):5918–22.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Chauffert B, Momex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19:1592–9.CrossRefPubMedGoogle Scholar
  4. Cloyd JM, Crane CH, Koay EJ, et al. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016;122(17):2671–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3496–502.CrossRefPubMedGoogle Scholar
  6. GITSG. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987;59(12):2006–10.CrossRefGoogle Scholar
  7. Goodman KA, Regine WF, Dawson LA, et al. Radiation therapy Oncology group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. Int J Radiat Oncol Biol Phys. 2012;83(3):901–8.CrossRefPubMedGoogle Scholar
  8. Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without Erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844–53.CrossRefGoogle Scholar
  9. Hazard L, Tward JD, Szabo A, et al. Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the surveillance, epidemiology, and end results (SEER) registry data. Cancer. 2007;11(10):2191–201.CrossRefGoogle Scholar
  10. Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010;17(4):981–90.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally-advanced pancreatic adenocarcinoma in GERCOR Phase II and III studies. J Clin Oncol. 2007;25:326–31.CrossRefPubMedGoogle Scholar
  12. Kalser M, Ellenberg S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899–903. Erratum in: Arch Surg 1986;121(9):1045CrossRefPubMedGoogle Scholar
  13. Katz SJ. Jama Surg. 2016;151(8):e161(3).Google Scholar
  14. Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guidelines. J Clin Oncol. 2016;34(21):2541–56.CrossRefPubMedGoogle Scholar
  15. Kim EJ, Ben-Josef E, Herman JM. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013;119(15):2692–700.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82. discussion 782-784CrossRefPubMedPubMedCentralGoogle Scholar
  17. Kooby DA, Gillespie TW, Liu Y, et al. Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. Ann Surg Oncol. 2013;20(11):3634–42.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007;110(1):47–55.CrossRefPubMedGoogle Scholar
  19. Loehrer PJ, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an eastern cooperative Oncology group trial. J Clin Oncol. 2011;29:4105–12.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015;54(7):979–85.CrossRefPubMedGoogle Scholar
  21. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the gastrointestinal tumor study group. Cancer. 1981;48(8):1705–10.CrossRefPubMedGoogle Scholar
  22. Morganti AG, Falconi M, van Stiphout RGPM, et al. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014;90(4):911–7.CrossRefPubMedGoogle Scholar
  23. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicenter, randomized, phase 2 trial. Lancet Oncol. 2013;14:317–26.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Murphy JD, Adusumilli S, Griffith KA, et al. Full dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68:801–8.CrossRefPubMedGoogle Scholar
  25. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576–85.CrossRefGoogle Scholar
  26. Neoptolemos JP, Stocken DD, Friess H, et al.; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10. Erratum in: N Engl J Med 2004; 351(7):726.Google Scholar
  27. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81.CrossRefGoogle Scholar
  28. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicenter, open-label, randomized, phase 3 trial. Lancet. 2017.  https://doi.org/10.1016/S0140-6736(16)32409-6.
  29. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer (CONKO-001). JAMA. 2007;297(3):267–76.CrossRefGoogle Scholar
  30. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.CrossRefGoogle Scholar
  31. Petrelli F, Comito T, Ghidini A, et al. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials. Int J Radiat Oncol Biol Phys. 2017;97(2):313–22.CrossRefPubMedGoogle Scholar
  32. Pollom EL, Alagappan M, von Eyben R, et al. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Int J Radiat Oncol Biol Phys. 2014;90(4):918–25.CrossRefPubMedGoogle Scholar
  33. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma. JAMA. 2008;299(9):1019–26.CrossRefGoogle Scholar
  34. Smeenk HG, van Eijck CHJ, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of the EORTC trial 40891. Ann Surg. 2007;246(5):734–40.CrossRefPubMedGoogle Scholar
  35. Tyvin R, Harris J, Abrams R, et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol. 2004;27:51–6.CrossRefGoogle Scholar
  36. Van Laethem J-L, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28(29):4450–6.CrossRefPubMedPubMedCentralGoogle Scholar
  37. Yovino S, Poppe M, Jabbour S, et al. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys. 2011;79(1):158–62.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Radiation Oncology, University of California San FranciscoMarin General HospitalSan FranciscoUSA
  2. 2.Department of Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations